A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization

PR Newswire12-12

Modern commercial data helps organizations find new patients and HCPs PLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490807490?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/V1tYt2TF5TCvRPlZaWE1Aw--~B/aD05Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b2bc42ae734f8649ca69684cb61ec5e7","is_english":true,"pubTime":"2024-12-12 20:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490807490","market":"us","top_or_hot":-1,"title":"A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization","media":"PR Newswire","content":"<div>\n<p>Modern commercial data helps organizations find new patients and HCPs\nPLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass...</p>\n\n<a href=\"https://finance.yahoo.com/news/growing-number-biopharmas-leverage-veeva-120300025.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 20:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/growing-number-biopharmas-leverage-veeva-120300025.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Modern commercial data helps organizations find new patients and HCPs\nPLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass...</p>\n\n<a href=\"https://finance.yahoo.com/news/growing-number-biopharmas-leverage-veeva-120300025.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0266013472.USD","symbol_name":"AXA WF - Framlington Longevity Economy A Cap USD","start_time":0,"source_url":"https://finance.yahoo.com/news/growing-number-biopharmas-leverage-veeva-120300025.html","article_id":"2490807490","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/V1tYt2TF5TCvRPlZaWE1Aw--~B/aD05Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b2bc42ae734f8649ca69684cb61ec5e7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/growing-number-biopharmas-leverage-veeva-120300025.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490807490","pubTimestamp":1734004980,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Modern commercial data helps organizations find new patients and HCPs. PLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems  today announced increasing momentum for Veeva Compass Patient, an emerging leader for anonymous patient longitudinal data. With unlimited data access, daily data, and the most complete data network supporting both retail and specialty brands, Compass Patient helps commercial teams at biopharmas of all sizes better support key use cases like patient journey, market sizing, and field force activation.\"We are using Veeva Compass Patient for many of our brands as it helps us find more HCPs and patients than traditional sources,\" said Sridutta Rao, executive director of commercial data and analytics solutions at Bayer. \"Having unlimited access to a complete and modern dataset to generate insights for both retail prescriptions and in-office treatments gives us a better understanding of the entire patient journey.\". Veeva Forward-looking StatementsThis releas","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4528":"SaaS概念","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","VEEV":"Veeva Systems Inc.","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4504":"桥水持仓","GRO":"Brazil Potash Corp."},"translate_title":"越来越多的生物制药公司利用Veeva Compass患者来提高商业化水平","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRO":1,"VEEV":1},"content_text":"Modern commercial data helps organizations find new patients and HCPs\nPLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass Patient, an emerging leader for anonymous patient longitudinal data. With unlimited data access, daily data, and the most complete data network supporting both retail and specialty brands, Compass Patient helps commercial teams at biopharmas of all sizes better support key use cases like patient journey, market sizing, and field force activation.\n\n  \n\n\"We are using Veeva Compass Patient for many of our brands as it helps us find more HCPs and patients than traditional sources,\" said Sridutta Rao, executive director of commercial data and analytics solutions at Bayer. \"Having unlimited access to a complete and modern dataset to generate insights for both retail prescriptions and in-office treatments gives us a better understanding of the entire patient journey.\"\nCompass Patient is licensed for use at the brand level and includes unlimited data access to all patient data. The Compass data network includes more than 300 million patients in the U.S., over three million healthcare providers and clinicians, 80+ billion prescription and medical records, and more than seven years of patient history.\n\"Veeva Compass Patient is the next generation of patient data for life sciences,\" said Peter Stark, executive vice president and general manager of Veeva Compass. \"I'm excited to see our customer community growing and driving so much value through our partnership.\"\nVeeva Compass Suite includes Veeva Compass Prescriber, projected prescriptions and procedures at the HCP, HCO, and ZIP level for retail and non-retail products, and Veeva Compass National, projected prescriptions and procedures at the state and national level for retail and non-retail products. Veeva Compass is part of Veeva Data Cloud, the modern, connected data platform for life sciences, which includes Veeva OpenData and Veeva Link.\nAdditional InformationFor more on Veeva Compass, visit: veeva.com/Compass Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems\nAbout Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.\nVeeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.\nContact:Alison BorrisVeeva Systems925-226-8821alison.borris@veeva.com\n View original content to download multimedia:https://www.prnewswire.com/news-releases/a-growing-number-of-biopharmas-leverage-veeva-compass-patient-to-improve-commercialization-302329758.html\nSOURCE Veeva Systems","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490807490"}